Алынды: 05.03.2024/Қабылданды: 04.04.2024/Онлайн жарияланды: 29.04.2024
УДК 614.35:615.1:001.89 МРНТИ 76.75, 34.45
DOI: 10.53511/pharmkaz.2024.32.71.033
Г.Н. Амирханова,1 Л.С. Ермуханова,1 А.Н. Нурбақыт2, Т.П. Бейсенбаев3, К. Джусупов 4, М.К. Таушанова 1
1 «Марат Оспанов атындағы Батыс Қазақстан медицина университеті», КеАҚ Ақтөбе қ., Қазақстан Республикасы
2 «С.Ж. Асфендияров атындағы Қазақ ұлттық медицина университеті», КеАҚ Алматы қ , Қазақстан Республикасы
3 ШЖҚ МКК «Ақтөбе облыстық фтизиопульмонологиялық орталығы» , Ақтөбе қ., Қазақстан Республикасы
4 Халықаралық жоғары Медицина мектебі, Бішкек қ., Қырғызстан
ОЛЖЕТІМДІ ХАЛЫҚАРАЛЫҚ БАЗАЛАРДА ДӘРІЛІК ПРЕПАРАТТАРДЫ ФАЛЬСИФИКАЦИЯ ЖӨНІНДЕГІ
ЖАРИЯЛАНЫМДАРДЫ ТАЛДАУ
Түйін
Кіріспе: Сапасыз және жалған дәрі-дәрмектердің таралуы пандемия ретінде сипатталады және оның денсаулық
сақтау мен әлеуметтік-экономикалық жағдайларға, әсіресе табысы төмен және орташа елдерде өте ауыр
зардаптары жақсы құжатталған. Аталған мәселені тиімді шешу үшін әртүрлі географиялық аймақтарда, жеткізу
тізбегінің әртүрлі бөліктерінде және әртүрлі дәрілік түрлерде SF препараттарының таралуын сенімді бағалау өте
маңызды.
Мақсаты: Жарияланымдарды талдау және қол жетімді халықаралық дерекқорлар бойынша жалған дәрілік
препараттардың таралу мәселелерін зерттеу.
Зерттеу әдістері: Жүз елу бес мақала қосу критерийлеріне сәйкес келді, оның ішінде қажетті мәліметтерді алу
кезеңінен өткен – 8 мета-талдау. Сипаттамалық талдау жүргізілді, себебі сандық, сапалық қорытындылар мен
мәліметтер көп болды.
Нәтижелер:
Жалған және сапасыз дәрі-дәрмектер әлемдегі денсаулық сақтау мен экономикаға үлкен қауіп төндіреді. Мәселенің
қазіргі сипатын егжей-тегжейлі сипаттау және географиялық орналасуы, дәрі-дәрмек кластары және дәрідәрмектерді талдау түрі бойынша білім шектеулерін анықтау мүмкін емес.
Қорытынды:
Жүйелік шолу нәтижесінде 195 мақала анықталып, оның 167-сі қарауға жіберілді. Қолмен іздеу арқылы қосымша 11
мақала қосылды, нәтижесінде барлығы 155 жарамды мақала болды. Контрафактілі немесе сапасыз дәрідәрмектердің таралуының нақты көрсеткіштерін анықтау қиынға соғуы мүмкін және қол жетімді әдебиеттерде
шектеулі елдер деңгейінде жоғары сапалы дәрілік зерттеулерді қажет етеді.
Түйін сөздер: дәрілік препараттарды бұрмалау, жалған препараттардың таралуы, лицензияланбаған, сапасыз
медициналық өнімдер.
ӘДЕБИЕТТЕР ТІЗІМІ/ REFERENCES
1 Nayyar GM, Attaran A, Clark JP, Culzoni MJ, Fernandez FM, Herrington JE, Kendall M, Newton PN, Breman JG, 2015 Reply on
a pandemic of counterfeit drugs. Am J Trop Med Hyg92(Appendix6):113–118.
2 World Health Organization, 2017. Study on the public health and socio-economic impact of substandard and falsified
medical products. Available at: http://www.who.int/medicines/regulation/ssffc/publications/se-study-sf /en/ Accessed
February 4, 2021.
3 Ozawa S., Evans D.R. , Bessias S. , Haney D.G. , Yemeke T.T. , Lang S.K. , Herrington J.E. ,2018. Prevalence and estimated
economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and metaanalysis. JAMA Netw Open1:e181662.
4 Almuzaini T., Chunara I., Sammons H., 2013. Substandard and counterfeit medicines: a systematic review of the literature.
BMJ Open3: e002923.
5 Nayyar GM, Breman JG, Newton PN, Herrington J, 2012. Low-quality antimalarial drugs in Southeast Asia and sub-Saharan
Africa. LancetInfectDis12:488–496.
6 Kaur H et al. 2016. Fake antimalarials: start with the facts. MalarJ15:86.
7 Kigera S, Heide L, 2017. Low prevalence of substandard and falsified antimalarial drugs and antibiotics in public and
religious health facilities in southern Malawi. Am J TropMedHyg96:1124–1135.
8 Chikowe I, Osei-Safo D, Harrison JJ, Konadu DY, Addae-Mensah I, 2015. Post-marketing surveillance of antimalarial drugs
used in Malawi. Malar J14:127.
9 Министерство здравоохранения и социальных служб США, Управление по санитарному надзору за качеством
пищевых продуктов и медикаментов, Центр оценки и исследования лекарств (CDER) , 2006 г. Руководство для
промышленности. Исследование результатов испытаний, не соответствующих техническим требованиям (OOS), для
фармацевтического производства. Доступно по адресу: https://www.fda.gov/media/71001/download .
10 Olliaro E, Olliaro P, Ho CWL, Ravinetto R, 2020. Legal uncertainty – the gray area around substandard medicines: where
public health meets the law. Am J TropMedHyg102:262 –267.)
11 Newton PN et al. 2009. Guidelines for conducting field studies on the quality of medicines: a proposal. PLoS Med6:e52.
12 WHO, WHO Expert Committee on Specifications for Pharmaceutical Products, 2016. Guidelines for conducting field studies
on the quality of medicines. WHO Technical Report Series No. 996. Available at:
https://www.who.int/medicines/publications/pharmprep/trs_996/en/.
13 McManus D, Naughton BD, 2020. Systematic review of sample studies of substandard, falsified, unlicensed and
unregistered medicines: focus on context, prevalence and quality. BMJ Glob Health5:e002393.
14 Waller P. Pharmacoepidemiology – a tool of public health. Pharmacoepidemiol drug Saf. 2001;10(2):165–172.
15 Amin A.A., Snow R.V., Kokvaro G.O. Quality of sulfadoxine-pyrimethamine and amodiaquine products in the Kenyan retail
sector. Jay Clean Farm Ter. 2005;30(6):559–565.
16 World Health Organization. Substandard and counterfeit medicines. Geneva: World Health Organization; 2003. Available
at http://www.who.int/mediacentre/factsheets/2003/fs275/en/.
17 World Health Organization. What is substandard medicines? Geneva: World Health Organization; 2014. Available at:
http://www.who.int/medicines/services/counterfeit/faqs/06/en/.
18 USP Council Convention Section on Global Public Health; USP Panel of Experts, International Health Expert Committee;
USP Regionalization Team, Heyman ML, Williams RL. Ensuring global access to quality medicines: the role of USP. J Pharm Sci
2011;100(4):1280–1287.
19 Yankus V., Marks S. Counterfeit drugs: go to the nearest pharmacy with news for 2009. New York: American Council on
Science and Health; 2009. Available at: http://acsh.org/2006/08/counterfeit-drugs-coming-to-a-pharmacy-near-you-2/.
20 Wertheimer AI, Norris J. Protecting against substandard/counterfeit drugs: mitigating a macroeconomic pandemic. Res
Social Adm Pharm. 2009;5(1):4–16.
21 Clift K. Combating counterfeit, adulterated and substandard medicines: defining the way forward? London: Chatham
House; 2010.
http://www.chathamhouse.org/sites/default/files/public/Research/Global%20Health/1110bp_counterfeit.pdf.).
22 Dets M., Bourdillon-Esteve P. Substandard, counterfeit, falsely labeled, falsified and counterfeit (SSFFC) medical products:
a global surveillance and monitoring project. Geneva: World Health Organization; 2013. Available at: http://www.who
.int/medicines/technical_briefing/tbs/WHO_HQ_TBS_Oct_2013.pdf.
23 Newton PN, Lee SJ, Goodman S, et al. Guidelines for conducting field studies of drug quality: a proposal. PLOS Med.
2009;6(3):e52., Newton PN, Amin AA, Bird S, et al. Prioritizing public health issues in identifying substandard drugs. PLOS
Med. 2011; 8(12):e1001139.
24 Amin A.A., Kokvaro G.O. Quality of antimalarial drugs in Africa. J Clin Pharm Ther. 2007;32(5):429–440.
25 World Health Organization. International Working Group against Counterfeit Medical Products – IMPACT. Geneva, World
Health Organization; 2011. Available at: http://www.who.int/impact/en/.).
242
26 Cockburn R, Newton PN, Adyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and
governments must educate about the dangers. PLoS Med. 2005;2(4): e100.
27 McKee T.K., Liang B.A. Global trade in counterfeit drugs: patient safety and public health risks. J Pharm Sci.
2011;100(11):4571–4579.).
28 Kao SL, Chan SL, Tan B, et al. Unusual outbreak of hypoglycemia. N Engl J Med . 2009;360(7):734–736.
29 Leung S, Schieman S, Alban S A simple fluorescence assay for the quantification of OSCS in heparin. Anal Bioanal
Chemistry, 2011;399(2):673–680.
30 Davison M. Pharmaceutical Anti-Counterfeiting and the Real Dangers of Counterfeit Drugs. New Jersey: John Wiley & Sons
Inc.; 2011.
31 Holzgrabe U., Malet-Martino M. Analytical problems of counterfeiting and falsification of drugs – an NMR approach. J
Pharm biomedical anal. 2011;55(4):679–687.).
32 Moken MS, Counterfeit Pharmaceuticals: How They and Related Legislation, or Lack thereof, Contribute to Stubbornly
High and Rising Drug Prices Am J Law Med 2003;29(4):525–542.
33 Heyman ML, Williams RL. Ensuring global access to quality medicines: the role of USP. J Pharm Sci . 2011;100(4):1280–
1287.
34 Zeans RJ, Pharmacy’s role in the fight with counterfeit drugs. J Am Pharm Assoc (2003). 2008;48(4):e71–e88.).
35 Caudron JM, Ford N, Henkens M, Mase S, Kiddle-Monroe R, Pinel J. Substandard medicines in low-resource countries: a
problem that can no longer be ignored. Trop Med Int Health. 2008; 13(8):1062–1072. Fried M. Is this pill safe? Bad drugs, bad
decisions. CMAJ 2011;183(8):984.
36 Newton PN, Green MD Fernandez FM, Day NPJ, White NJ Counterfeit anti-infective drugs Lancet Infectious Dis
2006;6(9):602–613.
37 Nayyar GML, Breman JG, Newton PN ., Herrington J. Low-quality antimalarial drugs in Southeast Asia and sub-Saharan
Africa. Lancet Infectious Dis. 2012;12(6):488–496.
38 Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobials: a review of the scientific
evidence. J Antimicrobial Chemotherapy 2007; 60(2):214–236.
39 Abdulaziz Fahad Abdulaziz Alghannam, Zoe Aslanpour, Sarah Evans, Fabrizio Schifano, A systematic review of counterfeit
and substandard medicines in quality field studies. Department of Pharmacy, University of Hertfordshire, Hatfield,
Hertfordshire, UK. Published 29 September 2014 Volume 2014 – 3 Pages 71-88 DOI https://doi.org/10.2147/IPRP.S636902.
40 Baratta F., Germano A., Brusa P. The spread of counterfeit drugs in developing countries and the stability of galenic
substances stored for months under different conditions of temperature and relative humidity. Horvath Med J.
2012;53(2):173–184.
41 Nair A, Strauch S, Lauvo J, Jahnke RW, Dressman J: Are counterfeit or substandard anti-infective drugs causing treatment
failures in Papua New Guinea? J Pharm Sci 2011;100(11):5059–5068.
42 Bate R, Tren R, Mooney L, et al. A pilot study of the quality of essential medicines in two major Indian cities. PLOS ONE,
Richa PG, Msuya Z, Clark M, Johnson K, Ndomondo -Sigonda M, Lailoff T. Using minilabs to improve regulatory testing
capacity in resource-limited settings: the Tanzanian experience. Health Policy 2008;87(2):217–222.. 2009;4(6):e6003.
43 Puyo R., Bilong S., Boisier P. et al. Medicines information system in Yaounde and Niamey: a study of the population selling
and the quality of medicines distributed. Illegal drug trade in the markets of Yaounde (Cameroon) and Niamey (Niger):
characteristics of sellers and drug quality. Bull Soc Pathol Exot. 2008;101(2):113–118.
44 French., Sikhakhang L., Freudenthal S., Thomson G., Wahlström R. Knowledge and perceptions of drug quality among drug
sellers and users in Lao PDR. Health Policy Plan. 2004;19(6):391–401.
45 Taylor RB, Shakur O, Behrens RH. and others. Pharmacopoeial quality of drugs supplied from pharmacies in Nigeria.
Lancet. 2001;357(9272):1933–1936.
46 Shakur O, Taylor RB, Behrens RH. Estimating the prevalence of substandard medicines in developing countries. Trop Med
Int Health. 1997;2(9):839–845.
47 Bate R, Jin GZ, Mathur A. Does price reveal substandard drugs? Data from 17 countries. J Health Economics.
2011;30(6):1150–1163.
48 Sir M, Gandhi D, Carr R, Dayal A, Raghavan D, Sharma N. Need for better data on counterfeit drugs in developing countries:
a proposed standard methodology research piloted in Chennai, India. Jay Clean Farm Ter. 2011;36(4):488–495.
49 Bate R, Tren R, Hess K, Mooney L, Porter K. A pilot study comparing technologies for testing substandard drugs in the field.
African Journal of Pharmacy and Pharmacology. 2009;3(4):165–170.
50 Kayumba PK, Richa PG, Sheviyo D, et al. Quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and
Tanzania: influence of tropical storage conditions on dissolution in vitro. Jay Clean Farm Ter. 2004;29(4):331–338.)
51 Dorlo TP, Eggelte TA, de Vries PJ, Beinen JH. Characterization and identification of suspected counterfeit miltefosine
capsules. Analyst (London). 2012;137(5):1265–1274.
52 Stanton S, Koski A, Kofi P, Mirzabaghi E, Grady BL, Brook S. Quality of uterotonic medications: assessing the effectiveness
of injectable uterotonic medications purchased by simulated clients in three districts of Ghana. BMJ Open. 2012;2
(3):e000431.
53 Sikhakhang L, Freudenthal S, Thomson G, Wahlström R. Knowledge and perceptions of drug quality among drug sellers
and users in Lao PDR. Health Policy Plan 2004;19(6):391–401.
54 Said M.M., Gibbons S., Moffat A.S., Zlo M. Near-infrared spectroscopy (NIRS) and chemometric analysis of paracetamol
tablets from Malaysia and the UK: a spectral database study. Int J Pharm. 2011;415(1 –2):102–109.
55 Haruna B., Adaku O.E., Usifo Ko. Chemical equivalence study of four grades of α-methyldopa. J Chem Pharm Res.
2013;5(10):356–358.
56 Audu SA, Taiwo AE, Saidu CO, et al. Quantitative analysis of ten (10) different brands of chlorpheniramine tablets sold in
Maiduguri Metropolitan Council (MMC). J Chem Pharm Res. 2012;4(7):3637–3650.
57 Karlage KL, Franklin SJ, Mufich VK. et al. Comparative evaluation of pharmaceutical products obtained in Mexico:
complementing existing scientific data. Drug Dev Ind Pharm. 2012;38(7):808–814.
243
58 Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet S, Van Bortel L. Impact of tropical climate conditions on the
quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009;81(5):776–781.
59 Photiu F, Aravind S, Wang PP, Nerapuzi O. Impact of illegal trade on the quality of epoetin alfa in Thailand. Klin Ter.
2009;31(2):336–346.).
60 Stanton S, Koski A, Kofi P, Mirzabaghi E, Grady BL, Brook S. Quality of uterotonic medications: assessing the effectiveness
of injectable uterotonic medications purchased by simulated clients in three districts of Ghana. BMJ Open. 2012;2
(3):e000431.,
61 Caudron JM, Ford N, Henkens M, Mase S, Kiddle-Monroe R, Pinel J, 2008. Substandard medicines in low-resource
countries: a problem that can no longer be ignored. Trop MedIntHealth13:1062 –1072.
62 Newton P. N., Amin A. A., Bird S., Passmore P., Dukes J., Thomson J., Simons B., Bate R., Geren P. J., White, New Jersey, 2011.
Prioritizing public health issues in identifying substandard medicines. PLoS Med8:e1001139.
63 Johnston A, Holt DW, 2014. Substandard drugs: a potential public health crisis. Br JClinPharmacol78:218–243.,
64 Ozawa S, Evans DR, Bessias S, Haney DG, Yemeke TT, Lang SK, Herrington JE, 2018. Prevalence and estimated economic
burden of substandard and falsified drugs in low- and middle-income countries. JAMA Netw Open1:e181662.
65 Nayyar GML, Breman J. G., McKee T.K., Clark J.P., Hadju M., Littrell M., Herrington J.E., 2019. Counterfeit and substandard
drugs: stopping the pandemic. Am J TropMedHyg100:1058–1065.).
66 Garner B.A. _ 2014. Black Law Dictionary. St. Paul, MN: Thomson Reuters.
67 Note. Health care law is a branch of administrative law. The practice of public health is governed by the rules, procedures,
and principles of administrative law. Administrative law itself is a branch of public law. (Koyuncu A. _ 2008. Administrative
Law and Public Health. Kirch W., ed. Encyclopedia of Public Health. Dordrecht, Netherlands: Springer.
68 McKee T.K., 2018. Prevalence of substandard and falsified essential medicines: still an incomplete picture. JAMA Netw
Open 1: e181685. [ PubMed ] [ Google Scholar ], 4.
69 Kochvara A. Dressman J., 2017. Substandard and counterfeit drugs: a systematic assessment of prevalence and risks based
on data published from 2007 to 2016 . J Pharm. Sci 106 : 2921–2929. [ PubMed ] [ Google Scholar ].
70 World Health Organization, 2021. COVID-19 Dashboard. Available at: https://covid19.who.int/. Accessed 5 October 2020.,
World Health Organization, 2020. Full list of WHO warnings for medical products. Available at:
https://www.who.int/medicines/publications/drugalerts/en/. Accessed 16 April 2020.
71 Directorate of Pharmacy and Medicines of the Ministry of Public Health, Cameroon, 2008. Cartography and Evaluation
Approfondie des Systemes d’Approvisionnement et de Distribution des Médicaments et Autres Produits de Santé au
Cameroun. Available at: http://digicollection.org/hss /documents/s17824fr/s17824fr.pdf Accessed April 21, 2020.
72 Ministère de la Santé Publique du Cameroun, 2013. Politique Pharmaceutique Nationale, 2–43. Available at:
https://dpml.cm/images/Actualite/2021/Politique-pharmaceutique-nationale-Cameroun_PPN.pdf. By as of June 3, 2021.
73 Delepierre A. Guyot A. Carpentier A., 2012. Update on counterfeit antibiotics worldwide: risks to public health. Med Mal
Infect 42: 247–255. [ PubMed ] [ Google Scholar.
74 Fahad A. Alghannam A. Aslanpour Z. Evans S. Schifano F. , 2014. Systematic review of counterfeit and substandard drugs in
a quality field study . Integr Pharm Res Pract 3 : 71–88 [ Google Scholar ].
75 Fernandez FM Green, MD Newton PN, 2008. Prevalence and detection of counterfeit pharmaceuticals: a mini-review. Res
47:585–590. [ Google Scholar ].
76 Nayyar G.M.L. Breman J.G. Newton P.N. Herrington J, 2012. Poor quality antimalarial drugs in Southeast Asia and subSaharan Africa. Lancet Infect Dis 12:488–496. [ PubMed ] [ Google Scholar ]).
77 Health and Disease Sciences, 2021. Journal of Medicine and Health Sciences. Available at: https://www.hsdfmsb.org/index.php/hsd. Accessed March 17, 2021.
78 Data Observatory Infectious Diseases Data Observatory (IDDO), Infectious Disease Data Observatory, 2021.
79 Scientific Literature Quality Expert. Available at: https://www.iddo.org/mq-scientific-literature-surveyor. Accessed
September 9, 2020).
80 World Health Organization, 2007. Survey of the quality of antiretroviral drugs circulating in selected African countries.
Available at: https://www.who.int/medicines/publications/ARV_survey.pdf. Accessed 20 April 2020.
81 Jobeth M.P. Singhe D. Lohoue J. Quaban S. Ngogang J. Tambo E. 2017. Monitoring and quality assurance of the
antiretroviral therapy supply chain in improving therapeutic outcomes for people living with HIV in Cameroon. AIDS Res
Ther 14 : 1–8. [ PMC free article ] [ PubMed ] [ Google Scholar ].
82 World Health Organization, 2011. Study of the quality of selected antimalarial drugs circulating in six countries in subSaharan Africa. Available at: http://www.who.int/medicines/publications/WHO_QAMSA_report.pdf. Accessed 25 April 2020.
83 Nnanga NE Ebumbu MEC Ngene JP Ewudou MER Mpondo ME, 2015. Assessing the pharmacotechnical evaluation of
molecules counteracting harmful effects in legal and illegal marches in Yaoundé: cas de l’arteméther–luméfantrine 20 /120
Health Science Dis 16: 1–5 [Google Scholar].
84 Basco LK 2004 Molecular epidemiology of malaria in Cameroon XIX Quality of antimalarial drugs used for self-medication
Am J Trop Med Hyg 70: 245–250. [PubMed] [Google Scholar].
85 Sawadogo KV, Amoud Al-Qamarani M, Al-Mekhlafi HM, Elkarban M, Al-Adroi AH, Cerra & Boukluz A, 2011. Quality
chloroquine tablets available in Africa. Ann Trop Med Parasitol 105:447–453. [ PMC free article ] [ PubMed ] [ Google Scholar
]),
86 Nnanga N.E. Tamdem G.S. Manga M.R. Sijuyi L.S. Mpondo, MEA, 2016. Pharmaceutical control of brands of ibuprofen
tablets sold in the formal and informal sectors in Cameroon. IDIAS 17: 284–290. [ Google Scholar ].
87 Nnanga NE Soppo LV Dassau I Nyangono NM Benga MF Ondua SL, 2020. Quality assessment of paracetamol and ibuprofen
analgesics sold in Douala (Cameroon).Science Health Dis 21: 118–122 [Google Scholar].
88 Nnanga NE Tanga TR Soppo LV Ngobo EBL Kojom LP Tiekwe E Adiogo D Mpondo ME Nkoa T, 2018. Stability assessment
of cotrimoxazole at a dose of 240 mg/5 ml, commercial suspension in the form and information schemes in the city of Douala.
Health Science. Dis 19 : 66–71 [Google Scholar].
244
89 Nnanga NE, Tabi OILT, Kidik PMK, Vandi D, Tsala DE, Sijui L, Mpondo MEA, 2016. Quality assessment of cotrimoxazole 480
mg marketed dose in Douala (Cameroon) IDIAS 15: 926–935 [Google Scholar].
90 Soppo LCV Nnanga NE Ze MJ, 2018. Evaluation of the quality of ceftriaxone at the Yaounde race circuit. CaHReF, Yaoundé
Congress Hall 08. Available at: http://cahref.masante-cam.org/node/479. Accessed May 10, 2020.
91 Joko E. Ngamo J. Tekam J. M., 2018. Quality control of antiparasitic imidazole drugs distributed in Bafoussam: albendazole,
mebendazole and metronidazole. IJRIAR 2: 79–90. [Google Scholar]
92 Nnanga NE Ovona M L.J. Etame L.G. Abaa, M.D. Nnomo A.K. Olinga M.F. Arrey A.H. Menyeng M.A.A. Mpondo M.E., 2016.
Qualitative assessment of commercial drugs albendazole, mebendazole and praziquantel in Yaounde City. Health Science Dis
17: 2–7. [Google Scholar],
93 Guetchueng ST Nnanga EN, 2014. Review of quality control assessment of brands of mebendazole 100 mg tablets in illicit
pharmacies. Int J Pharmacol Pharm Sci 6: 355–357. [Google Scholar].
94 Nnanga NE, Tabi OILT, Kidik PMK, Vandi D, Tsala DE, Sijui L, Mpondo MEA, 2016. Quality assessment of cotrimoxazole 480
mg marketed dose in Douala (Cameroon) IDIAS 15: 926–935 [Google Scholar].
95 Petersen A, Held N, Heide L, 2017. Surveillance of counterfeit and substandard medicines in Africa and Asia by local
organizations using a low-cost GPHF mini-laboratory. PLoS One 12 : e0184165. [ PMC free article ] [ PubMed ] [ Google
Scholar ].
96 Brusa P. Baratta F. Germano A., 2012. Distribution of counterfeit medicines in developing countries and the stability of
galenic substances stored for several months under different conditions of temperature and relative humidity. Croat Med J
53:173–184. [ PMC free article ] [ PubMed ] [ Google Scholar ],
97 Pouillot R Bilong C Boisier P Ciss M Moumouni A Amani I Nabeth P, 2008. Medicines information system in Yaounde and
Niamey: a study of seller population and quality of medicines distributed . Bull Soc Pathol Exot 2: 113–118. [ PubMed ] [
Google Scholar ].
98 Schäfermann S et al. 2020. Substandard and falsified antibiotics and drugs against noncommunicable diseases in western
Cameroon and northeastern Democratic Republic of the Congo. Am J Trop Med Hyg 103:894–908. [ PMC free article ] [
PubMed ] [ Google Scholar ].
99 Tabernero P. Fernandez F. M. Green, MD Guerin P. J. Newton P. N., 2014. Mind the Gaps: The Epidemiology of Substandard
Antimalarial Drugs in a Malarial World: An Analysis of the Global Control Network Database malaria Malar J 139. [ PMC free
article ] [ PubMed ] [ Google Scholar ].
100 Chida S, Newton PN, Guerin P, 2016. A systematic review of antibiotic quality. : Graduate work. Institute of Health and
Society, Faculty of Community Medicine, University of Oslo. Available at:
https://www.duo.uio.no/bitstream/handle/10852/51279/Scott-Thesis-FinalV.pdf?sequence=1 . Accessed May 15, 2020).
101 Vickers S. Bernier M. Zambrzycki S. Fernandez F. M. Newton P. N. Caillet S., 2018. Field detection devices for drug quality
testing: a systematic review. BMJ Glob Health 3: 725. [ Free article PMC ] [ PubMed ] [ Google Scholar ].
102 Sacre PY et al. 2010. Comparison and combination of spectroscopic methods for the detection of counterfeit drugs. J
Pharm Biomed Anal 53: 445–453. [ PubMed ] [ Google Scholar ] Storme-Paris I et al. 2010. Complex ability discriminative
power of near-infrared spectroscopy for the detection of counterfeit pharmaceuticals. Anal Chim Acta 658:163–174.
[PubMed] [Google Scholar].
103 Christelle Ange Waffo Chunga, Pierre-Yves Sacre, Patient Siza Khamuli, Rose Ngono Mballa, Emmanuel Nnanga Nga,
Philippe Hubert, and Roland Marini Jang’einga. Substandard medicines in Cameroon: a critical review. Am J Trop Med Hyg.
2021 August; 105(2):284–294.
104 Published online June 14, 2021. doi: 10.4269/ajtmh.20-1346.).
105 Pouillot R, Bilong C, Boisier P, Ciss M, Moumouni, A Amani, I Nabeth P, 2008. Medicines information system in Yaounde
and Niamey: a study of the population of sellers and the quality of medicines distributed. Bull Soc Pathol Exot 2: 113–118. [
PubMed ] [ Google Scholar ].
106 Tschida et al. (Chida S., Newton P.N., Geren P., 2016. A systematic review of the quality of antibiotics. : Master’s thesis.
Institute of Health and Society, Faculty of Community Medicine, University of Oslo. Available at: https://www.duo.
uio.no/bitstream/handle/10852/51279/Scott-Thesis-FinalV.pdf?sequence=1. Accessed May 15, 2020).
107 Jobeth M.P. Singhe D. Lohoue J. Quaban S. Ngogang J. Tambo E., 2017. Monitoring and quality assurance of the
antiretroviral therapy supply chain in improving therapeutic outcomes for people living with HIV in Cameroon. AIDS Res
Ther 14 : 1–8. [ PMC free article ] [ PubMed ] [ Google Scholar ].
108 Newton PN et al. 2009. Guidelines and recommendations for field studies of drug quality: a proposal. PLoS Med 6:
e1000052. [ PMC free article ] [ PubMed ] [ Google Scholar ].
109 Ньютон П.Н. и др. 2009. Руководящие принципы и рекомендации по полевым исследованиям качества
лекарственных средств: предложение . PLoS Med 6 : e1000052. [ Бесплатная статья о PMC ] [ PubMed ] [ Google
Scholar ].
110 Tabernero P et al. 2016. Ethical issues in the design and conduct of drug quality studies . Trop Med Int Health 21: 799–
806. [ PMC free article ] [ PubMed ] [ Google Scholar ]).
111 Djoko E Ngamo J Tekam JM 2018 Quality control of antiparasitic drugs imidazole drugs distributed in Bafoussam:
albendazole, mebendazole and metronidazole. IJRIAR 2: 79–90. [ Google Scholar ].
112 Schiavetti B et al. 2018. Quality of medicines used by children supplied by private pharmaceutical wholesalers in
Kinshasa, Democratic Republic of the Congo: a prospective study. Am J Trop Med Hyg 98:894–903. [ PMC free article ] [
PubMed ] [ Google Scholar ].
113 World Health Organization, 2020. Complete list of WHO warnings for medical products. Available at:
https://www.who.int/medicines/publications/drugalerts/en/. Accessed April 16, 2020, 23. Infectious Disease Data
Observatory, 2021. Scientific Literature Quality Expert. Available at: https://www.iddo.org/mq-scientific-literature-surveyor.
Accessed September 9, 2020.
114 Global Pharmaceutical Health Foundation, 2021. GPHF-Minilab TM: Counterfeit Medicines Fact Sheet. Available at:
https://www.gphf.org/en/minilab/hintergrund.htm. Accessed May 11, 2021.
245
115 Infectious Disease Data Observatory 2021. Scientific Literature Quality Expert. Available at: https://www.iddo.org/mqscientific-literature-surveyor. Accessed September 9, 2020.
116 Department of Health, Directorate of Pharmaceuticals and Laboratories, 2021 Warnings . Available at:
https://dpml.cm/index.php/fr/s-informer/alertes. Accessed May 11, 2021.
117 Ministry of Health, Directorate of Pharmaceutical Medicines and Laboratories, 2021. Appeal of two counterfeit drugs
presented in Lomme, ayant pour Principe Actif la Céfixime . Available at: https://dpml.cm/index.php/fr/sinformer/alertes/annee-2018/343-circulation-de-deux-faux-medicaments-presentes-comme-ayant-pour-principe- actif. -lacefixime. Accessed May 11, 2021.
118 Medina E, Bel E, Suñé JM, 2016. Counterfeit medicines in Peru: a retrospective review (1997–2014). BMJ Open 6 : 10387.
[ PMC free article ] [ PubMed ] [ Google Scholar ].
119 Every tenth medical product in developing countries is of poor quality or falsified. World Health Organization. 2017.
November 28, [December 21, 2020]. https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developingcountries-is-substandard-or-falsified.].
120 Willmer, J. New Alliance Seeks to Fight the Plague of Counterfeit Drugs. SaiDevNet. 2021. December 14 [December 21,
2020]. https://www.scidev.net/global/news/new-alliance-seeks-to-fight-plague-of-fake-medicines/.
121 World Health Organization Medical Product Alert No. 3/2020. WHO rapid alerts. 2020. [2020-04-09].
https://www.who.int/news-room/detail/31-03-2020-medical-product-alert-n-3-2020.
122 Report of the fifth meeting of the Member States Mechanism on Substandard/Counterfeit/Falsely
Labeled/Falsified/Counterfeit Medical Products. World Health Organization. 2017. January 17 [2017-02-14].
https://apps.who.int/gb/sf/pdf_files/MSM5/A_MSM5_8-en.pdf.
123 Buckley G, Gostin LB, Lawrence O Gostin. Washington, DC: Institute of Medicine of the National Academies; 2013.
Confronting the Problem of Falsified and Substandard Medicines: Committee on Understanding the Global Public Health
Impact of Substandard, Falsified and Counterfeit Medical Products. [Google Scholar].
124 Jackson KD, Higgins SR, Laing SC, Mwila S, Kobayashi T, Ippolito MM, Silvia S, Ozawa S. Impact of substandard and
falsified antimalarial drugs in Zambia: application of a model SAFARI. BMC Public Health. July 9, 2020; 20 (1): 1083. doi:
10.1186/s12889-020-08852-w.https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-08852-w.
125 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
126 Bergey SM, Higgins SR, Evans DR, Lang SC, Erim D, Ozawa S. The economic impact of substandard and counterfeit
antimalarial drugs in Nigeria. PLOS One. 2019 August 15; 14(8):e0217910. doi: 10.1371/journal.pone.0217910.
https://dx.plos.org/10.1371/journal.pone.0217910. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
127 Ozawa S, Haney D, Bessias S. Modeling the economic impact of substandard and falsified antimalarial drugs in the
Democratic Republic of Congo. Am J Trop Med Hyg? 2019; 100:57. doi: 10.4269/ajtmh.18-0334. [ PMC free article ] [ PubMed
] [ CrossRef ] [ Google Scholar ].
128 Renschler R, Walters K, Newton P, Laxminarayan R. Estimated under-five mortality associated with poor quality
antimalarial drugs in sub-Saharan Africa. Am J Trop Med Hyg. June 2015; 92 (6 suppl): 119–126. doi: 10.4269/ajtmh.14-
0725. http://europepmc.org/abstract/MED/25897068. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
129 Rojas-Cortez R. Substandard, Falsified and Unregistered Medicines in Latin America, 2017-2018. Rev. Panam Salud
Public. 2020; 10:44. doi: 10.26633/rpsp.2020.125. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
130 Nayyar GM, Breman J, McKee T. Falsified and substandard medicines: stopping the pandemic. Am J Trop Med Hyg.
2019:8. doi: 10.4269/ajtmh.18-098. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
131 Ozawa S, Evans DR, Bessias S, Haney DG, Yemeke TT, Lang SK, Herrington J .E. Prevalence and estimated economic
burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis.
Opening JAMA Netw. 2018, August 3; 1(4):e181662. doi: 10.1001/jamanetworkopen.2018.1662.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2018.1662 . [ PMC free article
] [ PubMed ] [ CrossRef ] [ Google Scholar ].
132 Hodges S, Garnett E. A ghost in the data: evidence gaps and the problem of counterfeit drugs in global health research.
Global public health. 2020, March 31; 15(8):1103–1118. doi: 10.1080/17441692.2020.1744678. [ PMC free article ] [
PubMed ] [ CrossRef ] [ Google Scholar ].
133 Simonsen L, Gog JR, Olson D, Wiboud K. Infectious disease surveillance in the era of big data: towards faster and locally
relevant systems. J Infect Dis. December 1, 2016; 214(supplement_4): S380–S385. doi: 10.1093/infdis/jiw376.
http://europepmc.org/abstract/MED/28830112. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
134 Kirian ML, Weintraub JM. Predicting gastrointestinal disease from sales data of over-the-counter diarrhea medications in
the San Francisco Bay Area. BMC Med Inform Decis Mak. 2010, July 20; 10(1):39. doi: 10.1186/1472-6947-10-39.
https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-10-39. [ PMC free article ] [ PubMed ] [
CrossRef ] [ Google Scholar ].
135 Newton Paul N., Lee S., Goodman S., Fernandez Facundo M., Jung Shunmei, Phanuvong Suli, Kaur Harparkash, Amin
Abdinasir A., Whitty Christopher J.M., Cokwaro Gilbert O, Lindegard Niklas, Luculai Patrick, White Lisa J, Day Nicholas PJ,
Green Michael D, White Nicholas J. Recommendations for conducting field studies of drug quality: a proposal. PLoS Med 2009
Mar 24;6(3):e52.doi : 10.1371/journal.pmed.1000052. https://dx.plos.org/10.1371/journal.pmed.1000052. [ PMC free
article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
136 WHO Expert Committee on Specifications for Pharmaceutical Products (Guidelines for conducting quality studies of
medicinal products. WHO Technical Report Series, No. 2016. [2017-12-07].
http://apps.who.int/medicinedocs/documents/s22404en/s22404en.pdf
137 Vida RG, Merzel S, Jan Ester, Fittler A. Development of a framework for an integrated risk-based methodology in
assessing the hazards associated with medicinal products obtained via the Internet. Saudi Pharm J. Dec 2020; 28 (12): 1733–
1742. doi: 10.1016/j.jsps.2020.10.018. https://linkinghub.elsevier.com/retrieve/pii/S1319-0164(20)30260-7. [ PMC free
article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
246
138 World Health Organization, WHO. Traditional Medicine Strategy 2002-2005. 2002. Geneva, Switzerland., 2. Umair M.,
Altaf M., Abbasi A. M. Ethnobotanical Study of Local Medicinal Plants in Hafizabad District, Punjab, Pakistan PLOS ON
2017;2.10.1371/journal.pone.0177912. [ PMC free article ] [ PubMed ] [ CrossRef ].
139 Umair M, Altaf M, Abbasi AM. Ethnobotanical study of indigenous medicinal plants in Hafizabad district, Punjab, Pakistan.
PLOS ON 2017;2. 10.1371/journal.pone.0177912. [ PMC free article ] [ PubMed ] [ CrossRef ].
140 Kosalets I, Cvek J, Tomic S. Contaminants of medicinal herbs and plant products. Arch Ind Hyg Toxicol. 2009; 60 (4): 485–
501. [ PubMed ] [ Google Scholar ].
141 Danladi A. , Inabo I, Yakubu E, Olonitola S. Contamination of herbal medicinal products sold in Kaduna city by selected
pathogenic bacteria. Afr J Tradit Complement Altern Med. 2009;6(1):70–77. [ Free article about PMC ] [ PubMed ] [ Google
Scholar ].
142 Khattak F. Microbiological quality assessment of commercially available medicinal plants in Peshawar city, Pakistan. Pak
J Bot 2012;44(4):1203–1208. [ Google Scholar ].
143 Medeiros P.M., Ladio A.H., Alburqueque U.P. Patterns of medicinal plant use among residents of urban and rural areas of
Brazil: a macro-scale study based on the available literature. J Ethnopharmacol. 2013; 150: 729–749. doi: 10.1016/j
.jep.2013.09.026. [ PubMed ] [ CrossRef ] [ Google Scholar ].
144 Bardia A., Nisley N.L., Zimmerman M.B., Gryzlak B.M., Wallace R.B. Evidence-based herbal use among adults: evidence
from the National Health Service. Interview Poll Clin Study. 2007; 82: 561–566. doi: 10.4065/82.5.561. [ PMC free article ] [
PubMed ] [ CrossRef ] [ Google Scholar ].
145 Almeida ST, Valentim AL, Diefenbach N. Lian Gong in the role of preventive physical therapy practice. Envelhecimento
Interdisciplinary Research. 2004; 6 (1): 103–110. [ Google Scholar ].
146 Chiwinski S , Montibel A, Braz ALO The importance of exercise without development Unifebe Review 2011;9(1):163–175
[Google Scholar].
147 Sousa PM, Sousa LL, Silveira CAN. National Therapeutic Formula, 2008. Brasilia: Ministério da Saúde; 2008.
Pharmaceuticals; pp. 26–29p. [ Google Scholar ].
148 Fameo E.B., Clarke A.M., Afolayan A.J. Identification of bacterial contaminants in herbal medicines used to treat
tuberculosis in the Amatole region of the Eastern Cape, South Africa, using the rapid 16S rRNA method. J Health Popul Nutr
2016;35(1):27. doi: 10.1186/s41043-016-0064-y. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
149 Report of the fifth meeting of the Member State mechanism on substandard/spurious/falsely
labeled/falsified/counterfeit medical products. World Health Organization. 2017. January 17 [2017-02-14].
https://apps.who.int/gb/ sf/pdf_files/MSM5/A_MSM5_8-en.pdf.
150 WHO Expert Committee on Specifications of Pharmaceutical Products. Guidelines for conducting quality studies of
medicinal products. WHO Technical Report Series, No. 2016. [2017-12-07].
http://apps.who.int/medicinedocs/documents/s22404en/s22404en .pdf 29).
151 List of World Health Organization Prequalified Quality Control Laboratories, 51st Edition. World Health Organization.
2021. [2021-02-03]. https://extranet.who.int/pqweb/medicines/medicines-quality -control-laboratories-list.
152 Vickers Serena, Bernier M, Zambrzycki S, Fernandez Facundo M, Newton Paul N, Kaye Celine. Field detection devices for
drug quality testing: a systematic review. BMJ Glob Health. 2018; 3(4): e000725. doi: 10.1136 /bmjgh-2018-000725.
https://gh.bmj.com/lookup/pmidlookup?view=long&pmid=30233826. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google
Scholar ].
153 UNAIDS. World Health Organization. A case study assessing HIV infection in a concentrated epidemic: lessons from
Indonesia. Geneva: UNAIDS; 2004. A case study assessing HIV infection in a concentrated epidemic: lessons from Indonesia.
[Google Scholar].
154 Pisani Elizabeth. The wisdom of whores: Bureaucrats, brothels and the business of AIDS. London: Granta; 2008. The
wisdom of whores: Bureaucrats, brothels and the business of AIDS. [Google Scholar].
155 Mahi Mary, Brown T., Stover J., Walker Neff, Stanecki Karen, Kirungi Wilford, Garcia-Calleja Txema, Gies Peter D. Getting
HIV estimates: from global advocacy to country planning and impact measurement. Global Health Action.
2017;10(sup1):1291169. doi: 10.1080/16549716.2017.1291169. http://europepmc.org/abstract/MED/28532304. [ PMC
free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ].
156 Abdulaziz Fahad Abdulaziz Alghannam, Zoe Aslanpour, Sarah Evans, Fabrizio Schifano, A systematic review of
counterfeit and substandard medicines in quality field studies. Department of Pharmacy, University of Hertfordshire,
Hatfield, Hertfordshire, UK. Published 29 September 2014 Volume 2014 – 3 Pages 71-88
DOI https://doi.org/10.2147/IPRP.S63690).
